A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Multi-center, fixed volume, randomized, double-blind, vehicle-controlled, parallel group,
dose escalation comparison study of TDM-105795 in male subjects, 18 to 55 years old, with
Androgenetic Alopecia (AGA).